Trump halts 250% tariff on EU pharma in latest agreement
The rising trade disputes between Washington and Brussels reached a pivotal point when former U.S. President Donald Trump decided to abandon proposals to introduce an unusually steep tariff—allegedly 250 percent—on pharmaceutical goods imported from the European Union. This move, included in a broader trade agreement, represents a crucial development in the prolonged discussions between the two significant economic forces and provides a temporary relief for businesses on both sides of the Atlantic.The dispute traces back to a period of intensifying trade frictions, during which Washington sought to correct what it viewed as persistent imbalances and unfair practices in sectors ranging…
